CSPC PHARMA (01093) Announces Clinical Trial Approval for Indacaterol-Mometasone Inhalation Treatment

Bulletin Express

Mar 05

On 5 March 2026, CSPC PHARMACEUTICAL GROUP LIMITED (CSPC PHARMA, 01093) announced that its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation obtained clinical trial approval in China from the National Medical Products Administration. This product is intended as a once-daily maintenance therapy for adults and adolescents aged 12 years and older with asthma not adequately controlled by inhaled corticosteroids and short-acting beta2-agonists.

Indacaterol is a long-acting beta2-agonist that relaxes smooth muscles and dilates the bronchi, while Mometasone Furoate acts as an inhaled corticosteroid with local anti-inflammatory properties. The combination is described as the first once-daily ICS-LABA dual therapy included in the National Reimbursement Drug List (2022 Edition). According to the announcement, this approval represents a major milestone in the company’s high-end innovative inhalation technology platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153750522"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153750522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153750522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153750522","market":"hk","top_or_hot":-1,"title":"CSPC PHARMA (01093) Announces Clinical Trial Approval for Indacaterol-Mometasone Inhalation Treatment","media":"Bulletin Express","content":"<p>On 5 March 2026, CSPC PHARMACEUTICAL GROUP LIMITED (CSPC PHARMA, 01093) announced that its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation obtained clinical trial approval in China from the National Medical Products Administration. This product is intended as a once-daily maintenance therapy for adults and adolescents aged 12 years and older with asthma not adequately controlled by inhaled corticosteroids and short-acting beta2-agonists.</p>\n<p>Indacaterol is a long-acting beta2-agonist that relaxes smooth muscles and dilates the bronchi, while Mometasone Furoate acts as an inhaled corticosteroid with local anti-inflammatory properties. The combination is described as the first once-daily ICS-LABA dual therapy included in the National Reimbursement Drug List (2022 Edition). According to the announcement, this approval represents a major milestone in the company’s high-end innovative inhalation technology platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC PHARMA (01093) Announces Clinical Trial Approval for Indacaterol-Mometasone Inhalation Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC PHARMA (01093) Announces Clinical Trial Approval for Indacaterol-Mometasone Inhalation Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 5 March 2026, CSPC PHARMACEUTICAL GROUP LIMITED (CSPC PHARMA, 01093) announced that its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation obtained clinical trial approval in China from the National Medical Products Administration. This product is intended as a once-daily maintenance therapy for adults and adolescents aged 12 years and older with asthma not adequately controlled by inhaled corticosteroids and short-acting beta2-agonists.</p>\n<p>Indacaterol is a long-acting beta2-agonist that relaxes smooth muscles and dilates the bronchi, while Mometasone Furoate acts as an inhaled corticosteroid with local anti-inflammatory properties. The combination is described as the first once-daily ICS-LABA dual therapy included in the National Reimbursement Drug List (2022 Edition). According to the announcement, this approval represents a major milestone in the company’s high-end innovative inhalation technology platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1153750522","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153750522","pubTimestamp":1772712181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 5 March 2026, CSPC PHARMACEUTICAL GROUP LIMITED (CSPC PHARMA, 01093) announced that its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation obtained clinical trial approval in China...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团(01093)公布茚达特罗-莫米松吸入治疗临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On 5 March 2026, CSPC PHARMACEUTICAL GROUP LIMITED (CSPC PHARMA, 01093) announced that its Indacaterol Acetate and Mometasone Furoate Powder for Inhalation obtained clinical trial approval in China from the National Medical Products Administration. This product is intended as a once-daily maintenance therapy for adults and adolescents aged 12 years and older with asthma not adequately controlled by inhaled corticosteroids and short-acting beta2-agonists.\nIndacaterol is a long-acting beta2-agonist that relaxes smooth muscles and dilates the bronchi, while Mometasone Furoate acts as an inhaled corticosteroid with local anti-inflammatory properties. The combination is described as the first once-daily ICS-LABA dual therapy included in the National Reimbursement Drug List (2022 Edition). According to the announcement, this approval represents a major milestone in the company’s high-end innovative inhalation technology platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}